Disentangling direct and weight-mediated effects of physical activity on health-related quality of life in a 12-month real-world digital lifestyle intervention.

Qual Life ResOct 22, 2026 (epub)

Isabel McCann, Anu Joki, Laura-Unnukka Suojanen et al.

✦ AI-curated · Sources linked

In 30 seconds

This longitudinal study examined physical activity and health-related quality of life (HRQoL) among 1,732 people participating in a 12-month digital lifestyle program; the abstract identifies it as a clinical trial but does not describe randomisation. Estimated mean activity rose from 2.16 to 3.06 MET-h/day (p < 0.001). Greater activity was associated with better scores in most HRQoL domains, with associations largely independent of weight change. For physical functioning and bodily pain, 84.9% and 88.0% of the total associations, respectively, were attributed to the direct pathway rather than mediation through BMI.

Key findings

  • Estimated mean physical activity increased from 2.16 to 3.06 MET-h/day (p < 0.001).
  • Within individuals, periods of higher-than-usual activity were associated with lower BMI (B = - 0.032, 95% CI - 0.053 to - 0.012).
  • Higher activity was associated with better scores in most HRQoL dimensions, including physical and mental component scores.
  • The direct pathway accounted for 84.9% of the total association with physical functioning and 88.0% with bodily pain.

Why it matters

The findings suggest that physical activity may relate to quality of life through pathways beyond weight change, including for mental as well as physical HRQoL measures. This distinction is relevant when evaluating lifestyle interventions: weight outcomes alone may not capture all potential quality-of-life associations. The results also support considering activity and weight management as related but distinct intervention goals, while recognising that the observed associations are modest.

What to keep in mind

Follow-up was incomplete, and the individual associations were modest. Physical activity and anthropometric measures relied on self-reported data.

Source

Published in Qual Life Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Preventive Medicine / Public Health

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.